Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fuxius, Stefan
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer	Active, not recruiting	3	866	Europe, Japan, US, RoW	Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasms, Neoplasm Metastasis	06/24	08/27
LUSPLUS, NCT05181592: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.	Recruiting	3	70	Europe	Luspatercept, Reblozyl	GWT-TUD GmbH, Celgene	Myelodysplastic Syndromes	12/24	06/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
NCT02131753: Therapy Optimisation for the Treatment of Hairy Cell Leukemia	Recruiting	2/3	210	Europe	Cladribine s.c. injection, HCL treatment, Litak(R), 2-CdA	University of Giessen	Hairy Cell Leukemia	12/25	12/27
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology	Completed	N/A	499	Europe		iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG	Advanced Solid Tumors or Hematologic Malignancies	06/23	06/23